Inhibitory effect of Angelica gigas on cold‑induced RhoA activation in vascular cells

Introduction

Raynaud's phenomenon (RP) is characterized by transient vasospasms within the fingers and/or toes, under cold or emotional stress conditions (1). RP is clinically classified into primary and secondary subtypes (2,3), however the pathogenesis is not fully understood. Whereas primary RP does not reflect any other disorders, secondary RP is closely associated with life-threatening morbidities, including autoimmune disease or scleroderma (1). The cold-induced molecular mechanisms in vascular cells remain to be fully elucidated, however, previous research has indicated that cold-mediated vasoconstriction is regulated by ras homolog gene family member A (RhoA) (4–6). In endothelial cells (ECs), cold-induced RhoA activation increases the production of endothlein-1 (ET-1), a key vasoconstrictor in RP (7–9). Paracrine release of ET-1 from ECs activates RhoA in vascular smooth muscle cells (VSMCs) and pericytes (9–11). This RhoA activation induces the vasoconstriction of VSMCs (4,6). Therefore, targeting RhoA may be an effective strategy for treatment of RP.

Previous studies have investigated the biological and chemical efficacy of herbal medicines for the treatment of RP (4,12–16). Angelica gigas (AG) is currently used for the management of vascular diseases, including menopausal symptoms (17,18), atherosclerosis (19) and brain ischemia (20). The anti-vasoconstrictive effect of AG has been demonstrated in vitro and in vivo (21,22), suggesting that AG may be useful in managing the vascular dysfunction observed in RP. However, the effect of AG on cold-induced VSMC responses has not been studied.

The present study evaluated the inhibitory effect of AG on cold-induced vascular cell contraction. AG treatment inhibited cold- and ET-1-mediated RhoA activation in both pericytes and ECs. However, AG treatment had no effect on cold-induced ET-1 production in ECs. These results suggest that AG may be beneficial for relieving cold-induced vasoconstriction in RP, via the inhibition of RhoA.

Materials and methods

AG preparation and cell culture

AG was purchased from Hanpoong Pharm and Foods Company (Jeonju, Korea). AG roots were ground and subsequently extracted with 30% ethanol. The freeze-dried mixture was stored at −80°C. Human umbilical vein endothelial cells (HUVECs) were gifted by Kwang Seok Kim at Korea Institute of Radiological and Medical Science (Seoul, Korea). Human brain microvascular pericytes were purchased from ScienCell Research Laboratories, Inc. (1200; Carlsbad, CA, USA). HUVECs were cultured in endothelial medium supplemented with 5% fetal bovine serum (FBS) and 1% endothelial cell growth supplement, microvascular pericytes were cultured in pericyte medium supplemented with 5% FBS, 1% pericyte growth supplement, and 1% penicillin/streptomycin solution. FBS, growth supplements and media were purchased from ScienCell Research Laboratories, Inc. (Carlsbad, CA, USA). Cells were cultured at humidified incubator (5% CO2; 95% relative humidity) at 37°C.

Western blot analysis

To investigate ET-1-mediated RhoA activation, pericytes were incubated with 100 nM/l ET-1 (Sigma-Aldrich, Merck KGaA, Darmstadt, Germany). To measure the inhibitory effect of AG on cold-induced RhoA activation, HUVECs and pericytes were pretreated with AG (100 or 200 µg/ml) for 30 min, followed by a warm (37°C) or cold (25°C) incubation for 30 min. Cells were lysed for protein extraction using ice-cold radioimmunoprecipitation assay buffer containing 50 mM Tris-HCl, (pH 7.5), 150 mM NaCl, 1% triton X-100, 2 mM EDTA, 0.1% SDS and 1% sodium deoxycholate (R2002; Biosesang Co., Ltd., Seoul, Korea). The extracted proteins were mixed with sample buffer (EBA-1052; Daejeon, Korea) and boiled at 100°C for 10 min. Protein amount was analyzed by using Bio-Rad protein assay kit (500–0006; Bio-Rad GmbH, Munchen, Germany). Equal amount of proteins (10 µg) were separated by 8–12% SDS-PAGE and transferred onto a nitrocellulose blotting membrane. The blots were probed with the following primary antibodies: Mouse-anti-active RhoA monoclonal (26904; 1:500; NewEast Biosciences, Malvern, PA, USA), rabbit-anti-phospho-focal adhesion kinase (FAK) monoclonal (8556; 1:500) and rabbit-anti-proto-oncogene tyrosine-protein kinase Src (SRC) polyclonal (2101; 1:1,000; both from Cell Signaling Technology, Inc., Danvers, MA, USA), mouse-anti-phospho-extracellular signal-related kinase (ERK) monoclonal (sc7383; 1:1,000) and mouse-anti-β-actin monoclonal (sc73615; 1:1,000; both from Santa Cruz Biotechnology, Inc., Dallas, TX, USA). After blocking the membrane with 2% skim milk for non-phosphoform of proteins or 2% Bovine serum albumin (BSA) in TBST for phosphoform of proteins, primary antibodies were incubated with the membrane overnight at 4°C on a shaker. Secondary antibodies for mouse (7076; 1:1,000–3,000) and rabbit (074; 1:1,000–3,000) were purchased from Cell Signaling Technology (Danvers, MA, USA) and incubated with the membrane for 1 h at room temperature on shaker. Antibody-conjugated membranes were incubated with ECL reagent (DG-WP250; DoGen, Seoul, Korea).

ELISA

ET-1 production in HUVEC-conditioned medium was evaluated using an endothelin-1 ELISA kit, according to the manufacturer's protocol (ADI-900-020A; Enzo Life Sciences, Inc., Farmingdale, NY, USA).

Phalloidin staining

The cold-induced formation of stress fibers and focal adhesion complexes was assessed in HUVECs. Cells were treated as aforementioned, and fixed with 4% paraformaldehyde (Junsei Chemical Co., Ltd., Tokyo, Japan) for 30 min and permeabilized with 0.1% Triton X-100 (T8787; Sigma-Aldrich, Merck KGaA, Darmstadt, Germany) for 15 min. Cells were stained with rhodamine-phalloidin (R415; Thermo Fisher Scientific, Inc., Waltham, MA, USA). The cells were visualized with Olympus FV10i self-contained confocal laser system (Olympus America Inc., PA, USA).

Statistical analysis

The differences of means between the groups were analyzed one-way analysis of variance. P<0.05 was considered to indicate a statistically significant difference.

Results

AG reduces cold- and ET-1-induced RhoA activation in pericytes

Pericytes contribute to microvascular contraction; therefore, the inhibitory effect of AG on the activity of RhoA in cold- or ET-1-exposed pericytes was examined by western blotting with active RhoA-GTP monoclonal antibody. AG treatment inhibited cold-induced RhoA activation (Fig. 1A), and ET-1-induced RhoA activation (Fig. 1B).

Figure 1. AG reduces cold- and endothelin-1-induced RhoA activation in pericytes. (A) Expression of active RhoA was measured in pericytes pre-treated with AG (200 µg/ml) for 30 min, and then exposed to normal (37°C) or cold (25°C) temperatures. (B) RhoA expression was measured in pericytes pre-treated with AG (200 µg/ml) for 30 min, and then incubated with endothelin-1 (100 nM/l). β-actin served as the loading control. AG, Angelica gigas; RhoA, ras homolog gene family member A.

AG reduces cold-induced RhoA activation in HUVECs

The impact of AG treatment on cold-induced RhoA activation was investigated in HUVECs. AG treatment decreased cold-induced RhoA activation (Fig. 2). Therefore, AG treatment demonstrated an ability to inhibit cold-induced RhoA activation in both pericytes and HUVECs.

Figure 2. AG reduces cold-induced RhoA activation in HUVECs. HUVECs were pre-treated with AG (200 µg/ml) for 30 min and then exposed to normal (37°C) or cold (25°C) temperatures. Expression of active RhoA was measured by western blot analysis, β-actin served as the loading control. AG, Angelica gigas; RhoA, ras homolog gene family member A; HUVECs, human umbilical vein endothelial cells.

AG reduces cold-induced ET-1 production in HUVECs

ET-1 is produced by ECs and serves a key role in vasoconstriction under cold conditions (7–9). Therefore, the inhibitory effect of AG treatment on ET-1 production in cold-exposed ECs was examined. HUVECs exposed to cold for 30 min increased ET-1 production by approximately 2-fold compared with the cells under normal conditions (P<0.05), however, AG pretreatment did not impact on cold-induced ET-1 production (Fig. 3).

Figure 3. AG has no impact on cold-induced ET-1 production in HUVECs. HUVECs were pre-treated with AG (200 µg/ml) for 30 min and then exposed to normal (37°C) or cold (25°C) temperatures for 30 min. ET-1 was measured in cultured medium from HUVECs by ELISA. Experiments were performed in triplicate. Bars indicate the mean ± standard deviation. *P<0.05. AG, Angelica gigas; ET-1, endothelin-1; HUVECs, human umbilical vein endothelial cells; NS, not significant.

AG reduces the cold-mediated formation of stress fibers and focal adhesion complexes in HUVECs

Cold-mediated RhoA activation induces the phosphorylation of FAK, which stimulates the formation of stress fibers and focal adhesion complexes (4). Cold exposure induced the formation of stress fibers and focal adhesion complexes, whereas AG treatment limited these cold-mediated responses (Fig. 4A). Furthermore, FAK phosphorylation stimulates the phosphorylation of SRC and ERK, and western blot analysis demonstrated that the cold-induced phosphorylation of FAK, SRC and ERK was inhibited by AG treatment (Fig. 4B). Expression of unphosphorylated FAK, SRC and ERK was not changed (data not shown).

Figure 4. AG reduces the cold-mediated formation of stress fibers and focal adhesion complexes in HUVECs. (A) HUVECs were treated with AG (200 µg/ml) for 30 min and then exposed to normal (37°C) or cold (25°C) temperatures for 30 min. F-actin was detected by rhodamine-phalloidin staining. The experiment was performed triplicate, and three fields were imaged in each treatment group. Figures are of a representative image. Arrowheads indicate the formation of stress fibers and focal adhesion complexes (scale bar=50 µm). (B) Phosphorylated forms of FAK, SRC, and ERK were detected by western blot analysis, β-actin served as the loading control. AG, Angelica gigas; HUVECs, human umbilical vein endothelial cells; FAK, focal adhesion kinase; SRC, proto-oncogene tyrosine-protein kinase Src; ERK, extracellular signal-related kinase.

Discussion

AG has been used in the treatment vascular disorders, however its molecular mechanism remains unclear (18–21). The activation of RhoA may serve as an indicator for cold responses in vascular cells, however the cold-mediated mechanisms of RP remain to be elucidated (4–6). Our previous study demonstrated that cold-mediated contraction is tightly regulated by RhoA activity (4). In the present study, cold- and ET-1-induced RhoA activation in vascular cells was reduced by AG treatment. Furthermore, the data suggested that AG treatment may inhibit vascular cellular contraction via RhoA suppression, in HUVECs and pericytes. Although AG treatment did not affect cold-mediated ET-1 production in HUVECs, ET-1-mediated RhoA activation in pericytes was reduced, indicating that AG may demonstrate efficacy these cells. In addition, it may be hypothesized that cold-induced ET-1 production is likely to be regulated by a mechanism other than the RhoA-mediated pathway, suggesting that studies should be performed to elucidate the precise mechanism of cold-induced ET-1 production. However, further in vitro and in vivo experiments are necessary to elucidate which active compounds in AG are responsible for the observed RhoA-inhibitory effects. In addition, the results indicated that cold exposure may induce the formation of stress fibers and focal adhesion complexes, and these responses were reduced by AG treatment. Previous research has demonstrated that cell contraction and the formation of focal adhesions depend on RhoA signaling pathways (23,24). The present study indicated that AG treatment was able to inhibit cold-mediated RhoA activation, thus resulting in a blockade of RhoA-mediated cell contraction and formation of focal adhesion complexes. Therefore, AG inhibition of RhoA activation may suppress vascular cellular contraction in cold conditions.

In conclusion, the present study demonstrated the inhibitory effect of AG on cold-induced contractile responses in vascular cells. Targeting RhoA by AG may be a useful therapeutic strategy for the treatment of vascular diseases, including RP. Further in vitro and in vivo studies are required, and these should investigate the vasodilatory impact of AG, and elucidate the active compound responsible for these effects.

Acknowledgements

Human umbilical vein endothelial cells (HUVECs) were gifted by Kwang Seok Kim at Korea Institute of Radiological and Medical Science (Seoul, Korea). This study was supported by the Korean Medicine R&D Project of the Ministry of Health and Welfare (grant no. HI13C0530).

References